test_DMFS_06100.json

[
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 142.0000  g/L;\nThe ALB is 41.7000  g/L;\n The CRP is 2.6000  mg/L;\n The LDH is 246.4000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.8333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000261839.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.5000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 130.0000  g/L;\nThe ALB is 47.0000  g/L;\n The CRP is 13.0000  mg/L;\n The LDH is 142.0000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.4000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000245870.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 164.0000  g/L;\nThe ALB is 44.0000  g/L;\n The CRP is 1.4800  mg/L;\n The LDH is 192.3000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 67.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 74.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.8333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000312845.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 117.0000  g/L;\nThe ALB is 44.2000  g/L;\n The CRP is 6.7400  mg/L;\n The LDH is 173.2000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.8333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000273070.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 31.3000 copies/mL;\nThe EBV of after treatment is 8.7200  copies/m; \nThe HGB is 149.0000  g/L;\nThe ALB is 44.8000  g/L;\n The CRP is 8.9900  mg/L;\n The LDH is 213.6000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.8667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000232724.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 5.9500  copies/m; \nThe HGB is 134.0000  g/L;\nThe ALB is 37.7000  g/L;\n The CRP is 7.5200  mg/L;\n The LDH is 154.6000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.8333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000277869.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 1.8200  copies/m; \nThe HGB is 149.5000  g/L;\nThe ALB is 44.8000  g/L;\n The CRP is 0.2000  mg/L;\n The LDH is 156.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 72.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.6000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000235744.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 115.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 149.0000  g/L;\nThe ALB is 46.1000  g/L;\n The CRP is 1.0300  mg/L;\n The LDH is 178.6000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000279668.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 26.0000 copies/mL;\nThe EBV of after treatment is 3.2400  copies/m; \nThe HGB is 128.0000  g/L;\nThe ALB is 33.2000  g/L;\n The CRP is 59.5800  mg/L;\n The LDH is 177.5000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.0667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000270078.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 151.0000  g/L;\nThe ALB is 41.1000  g/L;\n The CRP is 1.1400  mg/L;\n The LDH is 175.8000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.7000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000260353.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.3000 copies/mL;\nThe EBV of after treatment is 14.2000  copies/m; \nThe HGB is 153.0000  g/L;\nThe ALB is 41.8000  g/L;\n The CRP is 21.7800  mg/L;\n The LDH is 205.4000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.1333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000282002.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.9100 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 155.4000  g/L;\nThe ALB is 46.0000  g/L;\n The CRP is 1.1600  mg/L;\n The LDH is 178.8000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 38.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.8000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000286520.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 370.0000 copies/mL;\nThe EBV of after treatment is 27.3000  copies/m; \nThe HGB is 159.0000  g/L;\nThe ALB is 45.0000  g/L;\n The CRP is 1.2000  mg/L;\n The LDH is 237.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 91.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.5333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000248281.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.7000 copies/mL;\nThe EBV of after treatment is 33.7000  copies/m; \nThe HGB is 146.0000  g/L;\nThe ALB is 44.3000  g/L;\n The CRP is 2.5200  mg/L;\n The LDH is 238.3000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 43.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.8667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000266402.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 179.0000 copies/mL;\nThe EBV of after treatment is 178.0000  copies/m; \nThe HGB is 123.7000  g/L;\nThe ALB is 34.1000  g/L;\n The CRP is 4.0500  mg/L;\n The LDH is 191.7000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.6667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000273661.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 75.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 130.5000  g/L;\nThe ALB is 38.0000  g/L;\n The CRP is 10.3700  mg/L;\n The LDH is 187.0000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 66.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.1667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000256588.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 748.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 142.1000  g/L;\nThe ALB is 41.6000  g/L;\n The CRP is 1.9800  mg/L;\n The LDH is 211.6000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 84.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.9000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000255975.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 380.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 152.0000  g/L;\nThe ALB is 41.0000  g/L;\n The CRP is 2.5000  mg/L;\n The LDH is 155.0000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 98.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 109.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.9667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000248157.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 133.8000  g/L;\nThe ALB is 42.0000  g/L;\n The CRP is 1.8500  mg/L;\n The LDH is 202.4000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.3667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000265790.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 27.6000 copies/mL;\nThe EBV of after treatment is 1.3700  copies/m; \nThe HGB is 154.0000  g/L;\nThe ALB is 42.6000  g/L;\n The CRP is 1.5900  mg/L;\n The LDH is 180.8000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.7667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000284734.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 117.0000  g/L;\nThe ALB is 44.0000  g/L;\n The CRP is 6.8000  mg/L;\n The LDH is 200.0000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 44.7000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000242134.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9760 copies/mL;\nThe EBV of after treatment is 0.2000  copies/m; \nThe HGB is 117.9000  g/L;\nThe ALB is 44.8000  g/L;\n The CRP is 0.9200  mg/L;\n The LDH is 154.1000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 40.5333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000296870.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 18.2000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 121.0000  g/L;\nThe ALB is 45.4000  g/L;\n The CRP is 0.7400  mg/L;\n The LDH is 364.8000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.1333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000305452.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 143.6000  g/L;\nThe ALB is 42.7000  g/L;\n The CRP is 4.9600  mg/L;\n The LDH is 137.7000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000261070.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 88.2000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 173.0000  g/L;\nThe ALB is 47.0000  g/L;\n The CRP is 0.4000  mg/L;\n The LDH is 225.0000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 99.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.7000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000244125.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 72 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.8100 copies/mL;\nThe EBV of after treatment is 4.5400  copies/m; \nThe HGB is 156.6000  g/L;\nThe ALB is 40.4000  g/L;\n The CRP is 2.6500  mg/L;\n The LDH is 174.0000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 30.1333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000298873.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.9700 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 115.0000  g/L;\nThe ALB is 40.7000  g/L;\n The CRP is 0.4000  mg/L;\n The LDH is 135.7000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.4333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000298786.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.8800 copies/mL;\nThe EBV of after treatment is 5.2200  copies/m; \nThe HGB is 147.0000  g/L;\nThe ALB is 42.5000  g/L;\n The CRP is 3.2800  mg/L;\n The LDH is 170.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 脑膜瘤术后:Post-meningioma surgery patients often experience immune system suppression, drug interactions, and physical weakness, which can affect the treatment outcomes of nasopharyngeal carcinoma. During the recovery period, the suppressed immune system may reduce the response to radiotherapy and chemotherapy, while increasing the risk of infections and other complications, ultimately affecting treatment tolerance and prognosis.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.6000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000298338.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9.2400 copies/mL;\nThe EBV of after treatment is 0.2480  copies/m; \nThe HGB is 137.9000  g/L;\nThe ALB is 41.3000  g/L;\n The CRP is 2.3000  mg/L;\n The LDH is 159.7000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 63.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.6000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000292612.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 627.0000 copies/mL;\nThe EBV of after treatment is 2.5500  copies/m; \nThe HGB is 123.6000  g/L;\nThe ALB is 40.5000  g/L;\n The CRP is 12.5400  mg/L;\n The LDH is 547.7000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.6667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000293115.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.4400 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 144.0000  g/L;\nThe ALB is 46.5000  g/L;\n The CRP is 0.7000  mg/L;\n The LDH is 228.0000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 66.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 86.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.3333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000287627.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 132.0000  g/L;\nThe ALB is 45.5000  g/L;\n The CRP is 2.7900  mg/L;\n The LDH is 194.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.7000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000288633.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 120.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 143.0000  g/L;\nThe ALB is 40.7000  g/L;\n The CRP is 6.6700  mg/L;\n The LDH is 204.0000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 81.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 91.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.6667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000282638.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 131.0000  g/L;\nThe ALB is 45.9000  g/L;\n The CRP is 1.1500  mg/L;\n The LDH is 160.9000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.9333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000279354.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 33.9000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 162.9000  g/L;\nThe ALB is 44.0000  g/L;\n The CRP is 0.4700  mg/L;\n The LDH is 164.5000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 95.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 61.5333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000267289.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.2400 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 147.0000  g/L;\nThe ALB is 44.0000  g/L;\n The CRP is 4.2700  mg/L;\n The LDH is 231.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 73.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.8667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000243616.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 179.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 155.0000  g/L;\nThe ALB is 47.0000  g/L;\n The CRP is 1.3700  mg/L;\n The LDH is 236.5000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.4333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000254368.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 129.0000  g/L;\nThe ALB is 47.0000  g/L;\n The CRP is 10.4400  mg/L;\n The LDH is 145.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 48.8333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000245190.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.5500 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 155.0000  g/L;\nThe ALB is 43.7000  g/L;\n The CRP is 0.6900  mg/L;\n The LDH is 206.9000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 93.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 103.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.1667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000236915.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1930.0000 copies/mL;\nThe EBV of after treatment is 4.6000  copies/m; \nThe HGB is 124.0000  g/L;\nThe ALB is 45.2000  g/L;\n The CRP is 7.2000  mg/L;\n The LDH is 175.4000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 35.8667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000241239.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.1500 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 148.1000  g/L;\nThe ALB is 44.4000  g/L;\n The CRP is 1.2200  mg/L;\n The LDH is 144.1000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 79.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.1667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000295076.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.3000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 145.0000  g/L;\nThe ALB is 39.0000  g/L;\n The CRP is 2.0700  mg/L;\n The LDH is 189.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.1333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000306771.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 41.5000 copies/mL;\nThe EBV of after treatment is 1.6200  copies/m; \nThe HGB is 135.0000  g/L;\nThe ALB is 40.2000  g/L;\n The CRP is 6.5800  mg/L;\n The LDH is 141.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.1667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000308595.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 154.0000  g/L;\nThe ALB is 43.8000  g/L;\n The CRP is 2.6000  mg/L;\n The LDH is 183.6000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 48.9333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000307689.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 133.0000  g/L;\nThe ALB is 45.0000  g/L;\n The CRP is 1.1600  mg/L;\n The LDH is 182.1000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 73.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.4000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000307119.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 63 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 135.3000  g/L;\nThe ALB is 44.0000  g/L;\n The CRP is 1.8600  mg/L;\n The LDH is 213.3000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.8667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000300624.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 152.0000  g/L;\nThe ALB is 45.6000  g/L;\n The CRP is 5.4300  mg/L;\n The LDH is 171.4000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000299841.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.6070  copies/m; \nThe HGB is 139.0000  g/L;\nThe ALB is 41.0000  g/L;\n The CRP is 1.9100  mg/L;\n The LDH is 176.6000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.7667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000300040.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 55.1000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 163.0000  g/L;\nThe ALB is 43.8000  g/L;\n The CRP is 5.1500  mg/L;\n The LDH is 193.1000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.5333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000272666.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.1700 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 147.6000  g/L;\nThe ALB is 49.0000  g/L;\n The CRP is 1.1700  mg/L;\n The LDH is 161.6000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 79.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.0333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000297853.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3600 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 144.0000  g/L;\nThe ALB is 46.6000  g/L;\n The CRP is 1.0100  mg/L;\n The LDH is 152.7000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 74.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 54.3000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000298212.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 6.3000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 135.7000  g/L;\nThe ALB is 42.5000  g/L;\n The CRP is 5.9700  mg/L;\n The LDH is 245.6000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000295728.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.4000 copies/mL;\nThe EBV of after treatment is 0.2340  copies/m; \nThe HGB is 108.9000  g/L;\nThe ALB is 42.6000  g/L;\n The CRP is 0.2500  mg/L;\n The LDH is 154.8000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is Yes; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.4667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000292963.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.1500 copies/mL;\nThe EBV of after treatment is 0.4380  copies/m; \nThe HGB is 132.0000  g/L;\nThe ALB is 45.0000  g/L;\n The CRP is 2.3900  mg/L;\n The LDH is 210.8000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 55.3333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000293508.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.4050 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 138.8000  g/L;\nThe ALB is 44.3000  g/L;\n The CRP is 1.3000  mg/L;\n The LDH is 164.6000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.6667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000288429.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 93.7000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 147.0000  g/L;\nThe ALB is 46.6000  g/L;\n The CRP is 2.8700  mg/L;\n The LDH is 242.9000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.7667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000284894.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 294.0000 copies/mL;\nThe EBV of after treatment is 0.2670  copies/m; \nThe HGB is 138.2000  g/L;\nThe ALB is 39.0000  g/L;\n The CRP is 7.8300  mg/L;\n The LDH is 236.3000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.4000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000283742.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.9200 copies/mL;\nThe EBV of after treatment is 3.9200  copies/m; \nThe HGB is 164.0000  g/L;\nThe ALB is 40.8000  g/L;\n The CRP is 0.6700  mg/L;\n The LDH is 165.7000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.8667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000282593.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.5100 copies/mL;\nThe EBV of after treatment is 2.4500  copies/m; \nThe HGB is 138.9000  g/L;\nThe ALB is 35.4000  g/L;\n The CRP is 13.3000  mg/L;\n The LDH is 353.3000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 皮肌炎:Dermatomyositis is an autoimmune disease that may increase the risk of nasopharyngeal cancer and affect immune function and muscle health. For nasopharyngeal cancer patients, dermatomyositis can reduce treatment effectiveness, increase side effects, and lead to a poorer prognosis.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 43.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.1000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000280099.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 9.6700 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 145.0000  g/L;\nThe ALB is 42.9000  g/L;\n The CRP is 23.8900  mg/L;\n The LDH is 183.8000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000279379.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 142.0000  g/L;\nThe ALB is 41.7000  g/L;\n The CRP is 1.1300  mg/L;\n The LDH is 132.9000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.4333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000274804.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 84.7000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 153.0000  g/L;\nThe ALB is 43.8000  g/L;\n The CRP is 3.0300  mg/L;\n The LDH is 233.5000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.0000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000274517.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 34.1000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 154.0000  g/L;\nThe ALB is 45.2000  g/L;\n The CRP is 0.5500  mg/L;\n The LDH is 217.8000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 66.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 79.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.4000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000271630.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 7 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 147.0000  g/L;\nThe ALB is 38.9000  g/L;\n The CRP is 2.8300  mg/L;\n The LDH is 214.8000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 20 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.6667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000271099.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.5000 copies/mL;\nThe EBV of after treatment is 3.1900  copies/m; \nThe HGB is 146.9000  g/L;\nThe ALB is 44.7000  g/L;\n The CRP is 0.3700  mg/L;\n The LDH is 127.9000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 133.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 148.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.4000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000267775.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.9000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 144.3000  g/L;\nThe ALB is 42.4000  g/L;\n The CRP is 5.1000  mg/L;\n The LDH is 136.1000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.4333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000267834.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.7600 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 141.0000  g/L;\nThe ALB is 38.2000  g/L;\n The CRP is 10.1100  mg/L;\n The LDH is 183.8000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 58.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.9333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000265976.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 27.6000 copies/mL;\nThe EBV of after treatment is 2.9100  copies/m; \nThe HGB is 148.5000  g/L;\nThe ALB is 49.4000  g/L;\n The CRP is 0.8500  mg/L;\n The LDH is 195.5000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.9333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000266021.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 4.2400 copies/mL;\nThe EBV of after treatment is 1.9000  copies/m; \nThe HGB is 146.7000  g/L;\nThe ALB is 44.0000  g/L;\n The CRP is 0.2300  mg/L;\n The LDH is 131.2000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.0667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000263372.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.8000 copies/mL;\nThe EBV of after treatment is 1.0800  copies/m; \nThe HGB is 141.6000  g/L;\nThe ALB is 43.8000  g/L;\n The CRP is 5.1500  mg/L;\n The LDH is 193.1000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.1667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000263550.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.0700 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 145.3000  g/L;\nThe ALB is 45.5000  g/L;\n The CRP is 1.4600  mg/L;\n The LDH is 188.6000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.5000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000265846.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 158.0000  g/L;\nThe ALB is 44.8000  g/L;\n The CRP is 3.1800  mg/L;\n The LDH is 239.0000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.3667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000260229.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 8.5600 copies/mL;\nThe EBV of after treatment is 0.6950  copies/m; \nThe HGB is 106.0000  g/L;\nThe ALB is 39.0000  g/L;\n The CRP is 9.6000  mg/L;\n The LDH is 303.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.4333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000251017.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 158.8000  g/L;\nThe ALB is 45.9000  g/L;\n The CRP is 0.3800  mg/L;\n The LDH is 186.7000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.5000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000252786.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 860.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 164.0000  g/L;\nThe ALB is 45.0000  g/L;\n The CRP is 2.9000  mg/L;\n The LDH is 292.0000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 58.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.4667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000246227.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 201.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 127.0000  g/L;\nThe ALB is 41.0000  g/L;\n The CRP is 1.6000  mg/L;\n The LDH is 138.0000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 39.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.7667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000244878.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 164.0000  g/L;\nThe ALB is 46.0000  g/L;\n The CRP is 1.3000  mg/L;\n The LDH is 174.0000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.1333 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/00C1077175.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.9000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 142.0000  g/L;\nThe ALB is 45.9000  g/L;\n The CRP is 43.3200  mg/L;\n The LDH is 159.1000  U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.3000 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000240130.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.9600 copies/mL;\nThe EBV of after treatment is 0.0753  copies/m; \nThe HGB is 86.0000  g/L;\nThe ALB is 41.1000  g/L;\n The CRP is 2.2400  mg/L;\n The LDH is 180.1000  U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 87.9667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000237567.png"
        ]
    },
    {
        "conversations": [
            {
                "from": "human",
                "value": "<image>The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000  copies/m; \nThe HGB is 151.0000  g/L;\nThe ALB is 48.9000  g/L;\n The CRP is 1.4400  mg/L;\n The LDH is 217.2000  U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 94.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 99.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n"
            },
            {
                "from": "gpt",
                "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 92.9667 ### months."
            }
        ],
        "images": [
            "DMFS_test_80/0000230250.png"
        ]
    }
]